Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078966 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2MAP4K1NPC1CASRMAPT | |
| SCHEMBL3192274 | 0.82 | CASR (0.39) | SMN1; SMN2MAP4K1NPC1CASRMAPT | |
| SCHEMBL3075854 | 0.81 | NPC1 (0.37) | SMN1; SMN2MAP4K1NPC1MAPTALDH1A1 | |
| SCHEMBL29117063 | 0.78 | TLR8 (0.38) | SMN1; SMN2NPC1CASRTLR8 | |
| SCHEMBL23497850 | 0.77 | TLR8 (0.41) | NPC1CASRALDH1A1TLR8 | |
| SCHEMBL23497567 | 0.75 | PPARG (0.37) | MAP4K1NPC1MAPT | |
| SCHEMBL18764871 | 0.73 | ALDH1A1 (0.48) | SMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL3640575 | 0.72 | DGAT1 (0.31) | SMN1; SMN2 | |
| SCHEMBL23497845 | 0.70 | MAP4K1 (0.38) | MAP4K1NPC1MAPT | |
| SCHEMBL4061092 | 0.69 | MEN1 (0.54) | SMN1; SMN2NPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | SMN1; SMN2 4291/4885MAP4K1 661/4885NPC1 794/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | SMN1; SMN2 4291/4885MAP4K1 661/4885NPC1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.